General
Preferred name
BRETYLIUM
Synonyms
Bretylium tosilate ()
BRETYLIUM TOSYLATE ()
Bretylium (tosylate) ()
Bretylol ()
ASL-603 ()
NSC-62164 ()
Bretylium ion ()
Bretylium cation ()
P&D ID
PD009770
CAS
61-75-6
59-41-6
Tags
available
drug
Approved by
FDA
First approval
1986
Drug Status
approved
Drug indication
Cardiac Depressant (anti-arrhythmic)
Anti-Adrenergic
Ventricular fibrillation
Max Phase
Phase 4
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Bretylium is a substrate for the noradrenaline transporter so it accumulates inside nerve terminals which have this transporter. This accumulation underlies its inhibitory action on the sympathetic nervous system. Bretylium tosylate is no longer available in the US.
(GtoPdb)
DESCRIPTION
Adrenergic neuron blocking agent; antiarrhythmic; sympathomimetic
(LOPAC library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
0
Organisms
1
Compound Sets
20
Cayman Chemical Bioactives
ChEMBL Approved Drugs
ChEMBL Drugs
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
DrugMatrix
Enamine BioReference Compounds
Guide to Pharmacology
LOPAC library
MedChem Express Bioactive Compound Library
NCATS Inxight Approved Drugs
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
TargetMol Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
44
Molecular Weight
242.05
Hydrogen Bond Acceptors
0
Hydrogen Bond Donors
0
Rotatable Bonds
3
Ring Count
1
Aromatic Ring Count
1
cLogP
3.05
TPSA
0.0
Fraction CSP3
0.45
Chiral centers
0.0
Largest ring
6.0
QED
0.72
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Indication
ventricular arrhythmias, ventricular fibrillation (VF), ventricular tachycardia (VT)
Target
ATP1A1
Adrenergic Receptor
MOA
Norepinephrine inhibitor
Therapeutic Class
Antiarrhythmic Agents
Pathway
GPCR/G protein
Neuronal Signaling
Source data
